Detalles de la búsqueda
1.
Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials.
Oncology
; 92(5): 243-254, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28219073
2.
Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent ß thalassaemia.
Br J Haematol
; 168(6): 882-90, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25402221
3.
An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.
Am J Ther
; 21(3): 164-73, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-22713526
4.
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.
Am J Ophthalmol
; 260: 70-83, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37460036
5.
HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration.
Curr Eye Res
; 48(1): 44-50, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36398628
6.
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
Am J Ophthalmol
; 238: 157-172, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35038415
7.
Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
Clin Pharmacol Drug Dev
; 10(9): 1054-1063, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33932130
8.
Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers.
Clin Pharmacol
; 7: 11-7, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25653564
9.
A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects.
J Clin Pharmacol
; 53(4): 444-50, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23426978
10.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Cancer Chemother Pharmacol
; 72(2): 387-95, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23765178
11.
Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Clin Ther
; 35(3): 215-25, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23453404
12.
Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
Eur J Endocrinol
; 166(5): 821-8, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22383336
13.
A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
Drug Des Devel Ther
; 6: 71-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22573933
14.
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
Endocrine
; 42(2): 366-74, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22527887
15.
Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.
J Clin Pharmacol
; 52(4): 552-8, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22282526
16.
Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Clin Ther
; 34(3): 677-88, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22364824
17.
Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
J Clin Pharmacol
; 52(7): 1017-27, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21673137
Resultados
1 -
17
de 17
1
Próxima >
>>